HUE049556T2 - Szolúbilis fibroblaszt növekedési faktor receptor 3 (sFGFR3) polipeptid, vázszerkezetinövekedés-retardációs rendellenességek megelõzésében vagy kezelésében történõ alkalmazásra - Google Patents
Szolúbilis fibroblaszt növekedési faktor receptor 3 (sFGFR3) polipeptid, vázszerkezetinövekedés-retardációs rendellenességek megelõzésében vagy kezelésében történõ alkalmazásraInfo
- Publication number
- HUE049556T2 HUE049556T2 HUE14702206A HUE14702206A HUE049556T2 HU E049556 T2 HUE049556 T2 HU E049556T2 HU E14702206 A HUE14702206 A HU E14702206A HU E14702206 A HUE14702206 A HU E14702206A HU E049556 T2 HUE049556 T2 HU E049556T2
- Authority
- HU
- Hungary
- Prior art keywords
- sfgfr3
- polypeptide
- prevention
- treatment
- factor receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2013/001480 WO2014111744A1 (en) | 2013-01-16 | 2013-01-16 | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE049556T2 true HUE049556T2 (hu) | 2020-09-28 |
Family
ID=48289519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE14702206A HUE049556T2 (hu) | 2013-01-16 | 2014-01-16 | Szolúbilis fibroblaszt növekedési faktor receptor 3 (sFGFR3) polipeptid, vázszerkezetinövekedés-retardációs rendellenességek megelõzésében vagy kezelésében történõ alkalmazásra |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20150344855A1 (https=) |
| EP (2) | EP2945967B1 (https=) |
| JP (3) | JP2016506914A (https=) |
| KR (3) | KR20160002681A (https=) |
| CN (1) | CN105121464B (https=) |
| AU (2) | AU2013373679A1 (https=) |
| CA (2) | CA2898415A1 (https=) |
| DK (1) | DK2945967T3 (https=) |
| EA (2) | EA201591324A1 (https=) |
| ES (1) | ES2796743T3 (https=) |
| HU (1) | HUE049556T2 (https=) |
| IL (2) | IL239810A0 (https=) |
| MX (2) | MX372787B (https=) |
| PE (1) | PE20151664A1 (https=) |
| PL (1) | PL2945967T3 (https=) |
| PT (1) | PT2945967T (https=) |
| SG (2) | SG11201505488XA (https=) |
| SI (1) | SI2945967T1 (https=) |
| WO (2) | WO2014111744A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201591324A1 (ru) | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| EP3242888B8 (en) | 2015-01-07 | 2021-06-02 | Pfizer Inc. | Soluble fgfr3 decoys for treating skeletal growth disorders |
| KR101981774B1 (ko) * | 2016-04-25 | 2019-05-27 | 장부다 | Vr 공간에서 사용자 인터페이스를 제공하는 방법, 디바이스 및 기록매체 |
| MX2018016257A (es) | 2016-07-07 | 2019-11-21 | Therachon Sas | Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos. |
| JP7335247B2 (ja) * | 2017-09-20 | 2023-08-29 | ファイザー・インク | 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置 |
| CN108410803B (zh) * | 2018-03-28 | 2019-02-05 | 湖南源品细胞生物科技有限公司 | 一种诱导脂肪干细胞成软骨分化的培养方法和培养液 |
| CN110272900B (zh) * | 2019-04-19 | 2024-03-26 | 中国人民解放军陆军军医大学 | 用于制备骨骼发育异常猪模型的sgRNA及其应用 |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| WO2022254319A1 (en) | 2021-06-01 | 2022-12-08 | Pfizer Inc. | Cell culture method for producing sfgfr3 polypeptide |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| WO1996041620A1 (en) * | 1995-06-12 | 1996-12-27 | Yeda Research And Development Co., Ltd. | Fgfr3 as a marker for mesenchymal skeletal progenitor cells |
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| US7863020B2 (en) | 2000-06-28 | 2011-01-04 | Glycofi, Inc. | Production of sialylated N-glycans in lower eukaryotes |
| ES2252261T3 (es) | 2000-06-28 | 2006-05-16 | Glycofi, Inc. | Metodos para producir glicoproteinas modificadas. |
| US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
| AU2002235202A1 (en) * | 2000-12-18 | 2002-07-01 | Gene Logic, Inc. | Treatment of bone disorders by modulation of fgfr3 |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| JP2003104908A (ja) * | 2001-09-28 | 2003-04-09 | Ichikazu Nakao | 軟骨無形成症治療剤 |
| JP4252746B2 (ja) * | 2001-10-05 | 2009-04-08 | 一和 中尾 | 軟骨無形成症治療剤 |
| BRPI0203172B8 (pt) * | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| US7332299B2 (en) | 2003-02-20 | 2008-02-19 | Glycofi, Inc. | Endomannosidases in the modification of glycoproteins in eukaryotes |
| IL156495A0 (en) * | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| ES2374822T3 (es) | 2004-02-24 | 2012-02-22 | Allergan, Inc. | Ensayo de selección de toxinas botul�?nicas. |
| EP2083081A1 (en) * | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| US8101721B2 (en) | 2006-06-15 | 2012-01-24 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| EP2083846B1 (en) | 2006-09-28 | 2015-07-15 | Hepacore Ltd. | N-terminal fgf variants having increased receptor selectivity and uses thereof |
| AR063975A1 (es) | 2006-11-28 | 2009-03-04 | Centelion | Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada |
| WO2008133873A2 (en) * | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| US8426396B2 (en) | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
| EP2313435A4 (en) | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
| EP2318529B1 (en) | 2008-08-04 | 2017-10-18 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| AR073770A1 (es) | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
| MA33208B1 (fr) | 2009-03-25 | 2012-04-02 | Genentech Inc | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci |
| CN101585866B (zh) * | 2009-07-02 | 2011-10-05 | 中国人民解放军第三军医大学野战外科研究所 | 调节fgfr3活性的多肽及其筛选方法和应用 |
| US8445445B2 (en) | 2009-09-15 | 2013-05-21 | Five Prime Therapeutics, Inc. | Method of promoting hair growth using FGFR4 extracellular domains |
| LT2498799T (lt) | 2009-11-13 | 2016-11-10 | Five Prime Therapeutics, Inc. | Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis |
| WO2011084711A2 (en) | 2009-12-17 | 2011-07-14 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr3 extracellular domains |
| RU2012134637A (ru) | 2010-01-14 | 2014-02-20 | Йейл Юниверсити | Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| WO2012088608A1 (en) * | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
| CN102219860B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| JP6162707B2 (ja) | 2011-10-24 | 2017-07-12 | ハロザイム インコーポレイテッド | 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法 |
| FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| WO2014018673A2 (en) | 2012-07-24 | 2014-01-30 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| US20140030259A1 (en) | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| US11230589B2 (en) | 2012-11-05 | 2022-01-25 | Foundation Medicine, Inc. | Fusion molecules and uses thereof |
| EA201591324A1 (ru) | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| PE20170256A1 (es) | 2014-01-24 | 2017-04-22 | Ngm Biopharmaceuticals Inc | Proteinas de union y sus metodos de uso |
| EP3242888B8 (en) | 2015-01-07 | 2021-06-02 | Pfizer Inc. | Soluble fgfr3 decoys for treating skeletal growth disorders |
| MX2018016257A (es) | 2016-07-07 | 2019-11-21 | Therachon Sas | Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos. |
| JP7335247B2 (ja) | 2017-09-20 | 2023-08-29 | ファイザー・インク | 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置 |
-
2013
- 2013-01-16 EA EA201591324A patent/EA201591324A1/ru unknown
- 2013-01-16 SG SG11201505488XA patent/SG11201505488XA/en unknown
- 2013-01-16 JP JP2015553175A patent/JP2016506914A/ja not_active Withdrawn
- 2013-01-16 US US14/759,490 patent/US20150344855A1/en not_active Abandoned
- 2013-01-16 CA CA2898415A patent/CA2898415A1/en not_active Abandoned
- 2013-01-16 WO PCT/IB2013/001480 patent/WO2014111744A1/en not_active Ceased
- 2013-01-16 KR KR1020157022203A patent/KR20160002681A/ko not_active Withdrawn
- 2013-01-16 AU AU2013373679A patent/AU2013373679A1/en not_active Abandoned
-
2014
- 2014-01-16 KR KR1020157022078A patent/KR102249454B1/ko not_active Expired - Fee Related
- 2014-01-16 KR KR1020217013228A patent/KR20210054026A/ko not_active Withdrawn
- 2014-01-16 EP EP14702206.5A patent/EP2945967B1/en active Active
- 2014-01-16 ES ES14702206T patent/ES2796743T3/es active Active
- 2014-01-16 DK DK14702206.5T patent/DK2945967T3/da active
- 2014-01-16 PT PT147022065T patent/PT2945967T/pt unknown
- 2014-01-16 US US14/759,535 patent/US10724014B2/en not_active Expired - Fee Related
- 2014-01-16 EA EA201591055A patent/EA201591055A1/ru unknown
- 2014-01-16 SI SI201431607T patent/SI2945967T1/sl unknown
- 2014-01-16 PL PL14702206T patent/PL2945967T3/pl unknown
- 2014-01-16 WO PCT/EP2014/050800 patent/WO2014111467A1/en not_active Ceased
- 2014-01-16 EP EP20167861.2A patent/EP3736285A1/en not_active Withdrawn
- 2014-01-16 CN CN201480005077.6A patent/CN105121464B/zh not_active Expired - Fee Related
- 2014-01-16 MX MX2015009142A patent/MX372787B/es active IP Right Grant
- 2014-01-16 HU HUE14702206A patent/HUE049556T2/hu unknown
- 2014-01-16 PE PE2015001353A patent/PE20151664A1/es not_active Application Discontinuation
- 2014-01-16 CA CA2896978A patent/CA2896978A1/en active Pending
- 2014-01-16 AU AU2014206844A patent/AU2014206844A1/en not_active Abandoned
- 2014-01-16 SG SG11201505140XA patent/SG11201505140XA/en unknown
- 2014-01-16 JP JP2015553074A patent/JP2016506912A/ja not_active Withdrawn
-
2015
- 2015-07-06 IL IL239810A patent/IL239810A0/en unknown
- 2015-07-15 MX MX2019013857A patent/MX2019013857A/es unknown
- 2015-07-16 IL IL239996A patent/IL239996A0/en unknown
-
2019
- 2019-02-08 JP JP2019021752A patent/JP6995069B2/ja not_active Expired - Fee Related
- 2019-08-05 US US16/532,184 patent/US20200199545A1/en not_active Abandoned
-
2020
- 2020-03-13 US US16/818,954 patent/US11702642B2/en active Active
- 2020-06-19 US US16/906,046 patent/US11814654B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2025006I2 (el) | Συνθεσεις που περιλαμβανουν πολυπεπτιδα actriia για χρηση στη θεραπεια πνευμονικης υπερτασης | |
| HUE049556T2 (hu) | Szolúbilis fibroblaszt növekedési faktor receptor 3 (sFGFR3) polipeptid, vázszerkezetinövekedés-retardációs rendellenességek megelõzésében vagy kezelésében történõ alkalmazásra | |
| IL256166B (en) | Compounds for use in treating neuromuscular disorders | |
| DK2945642T3 (da) | Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme | |
| SI3675854T1 (sl) | Derivati piperidinil-indola za uporabo v zdravljenju glomerulopatije c3 | |
| IL245101B (en) | Derivatives of 1,4-cyclohexylamine and processes for their preparation | |
| PT3811943T (pt) | Composto para uso no tratamento de distúrbios oculares | |
| PL2968218T3 (pl) | Skojarzenie do leczenia choroby parkinsona | |
| LT4101454T (lt) | Kompozicijos, skirtos naudoti hipertenzijos gydymui | |
| ZA201804079B (en) | Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease, or in the diagnosis of parkinson's disease | |
| LT3687567T (lt) | Anti-adrenomedulino rišiklis, skirtas panaudoti taikant ligos simptomų terapiją arba profilaktiką | |
| PL3049100T3 (pl) | Zmodyfikowane czynniki wzrostu fibroblastu-1 do leczenia zaburzeń ocznych | |
| ZA201802399B (en) | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer | |
| EP3648789C0 (en) | MTMR2-S POLYPEPTIDE FOR USE IN THE TREATMENT OF MYOPATHY | |
| IL254766B (en) | A certain analog of trifluoroethyl quinoline for use in the treatment of Sjögren's syndrome | |
| GB2569682B (en) | Topical composition for use in the treatment of burns | |
| PT3177283T (pt) | Composto ativo e composição relacionada pata utilização dermatológica no campo farmacêutico ou cosmético | |
| GB201320506D0 (en) | Cyclic amino compounds for the use in the treatment of cardiac disorders | |
| HUE058845T2 (hu) | Nem biokonvertibilis C3-szubsztituált pregnenolon-származékok szerhasználati zavarok kezelésében történõ alkalmazásra |